MedXCell SA

MedXCell SA is a European biotechnology startup founded in 2016, headquartered in Switzerland, and with offices in the EU (France) and the US (Cambridge, MA). The company describes itself as a cell therapy venture builder with a strong industrial mindset and a global perspective. Its focus is on technologies, techniques, and novel applications in major diseases such as cancer, autoimmune, neurological, and degenerative disorders.

With a multidisciplinary expert team possessing entrepreneurial, clinical, operational, business development, and funding capabilities, MedXCell aims to drive innovation in the field of health care. The company recently secured a Fr.5.30M Series A investment on 04 June 2021. The investors for this round have not been disclosed.

Overall, MedXCell SA presents an intriguing proposition in the biotechnology and health care sectors, with its unique approach as a cell therapy venture builder. The recent investment indicates investor confidence in the company's potential for driving advancements in cell therapy technologies for addressing various diseases, which could position it as an attractive opportunity for venture capitalists seeking exposure to innovative biomedical solutions.